Gts Securities LLC Akebia Therapeutics, Inc. Call Options Transaction History

Gts Securities LLC

5 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q3 2024 Nov 13, 2024	SELL	$0.94 - $1.55 $12,878 - $21,235	-13,700 Reduced 45.36%	16,500 $21,000
Q2 2024 Aug 14, 2024	SELL	$0.86 - $1.63 $27,606 - $52,323	-32,100 Reduced 51.52%	30,200 $30,000
Q1 2024 May 15, 2024	SELL	$1.27 - $2.24 $25,019 - $44,128	-19,700 Reduced 24.02%	62,300 $114,000
Q4 2023 Feb 14, 2024	BUY	$0.8 - $1.28 $2,240 - $3,584	2,800 Added 3.54%	82,000 $101,000
Q3 2023 Nov 15, 2023	BUY	$0.87 - $1.84 $68,904 - $145,728	79,200 New	79,200 $90,000

121

54.8M

291K

179K

Ticker AKBA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 183,848,992
Market Cap $349M
Description
Akebia Therapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of therapeutics for patients with kidney diseases. The company's lead product investigational product candidate is vadadustat, an oral therapy, which is in Phase III development for the treatment of anemia due to chronic kidney disease (CKD) ...

Get notified when there are updates to the investment portfolio of Gts Securities LLC, based on Form 13F filings with the SEC.

Stay updated on Gts Securities LLC with notifications on news.